Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1952 results
September 2026
-
Press release
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based… -
Story Access to Healthcare
25 years of expanding access to cancer care
For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.
-
Ad hoc release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-… -
Ad hoc release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not… -
Ad hoc release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with…
July 2026
-
Press release
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in… -
Story Discovery
Smarter decisions at scale: How Novartis is using AI to advance R&D
Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients
-
Story People and Culture
Small shifts. Big impact. The leadership choices that matter most in the age of AI
There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change.
-
Story Discovery
How Novartis R&D is advancing the next breakthrough innovations
Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation
-
Ad hoc release
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den… -
Ad hoc release
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%…